Orphan Drug Market Access
Ensuring orphan drug access amidst a more challenging environment
  • April 19, 2017
  • Valid Insight

Thomas Mueller, Head of Pharmaceuticals at the Federal Joint Committee (G-BA), stated at the Pharma Pricing and Market Access Congress in London, February 2017, that the association of orphan drug status with high prices cannot continue and that the only way for orphan drug pricing to go is down. Yet, due to the small target […]

Challenging market access barriers for autoimmune disease therapies
  • April 10, 2017
  • Valid Insight

The global immunology market is expected to grow from $61.5 billion in 2015 to more than $74 billion by 2022.1 Autoimmune diseases, such as diabetes and rheumatoid arthritis, require life-long treatment and constitute one of the largest spending areas in healthcare. The prevalence of autoimmune diseases is also increasing annually.2 Clearly, this is a lucrative […]

Market access immuno-oncology
Improving market access to immuno-oncology therapies
  • April 4, 2017
  • Valid Insight

The number of unmet needs, whether clinical, economic or humanistic, remains high in oncology, especially for patients with metastatic conditions. With positive clinical trial results in many cancer types, including melanoma, colon cancer, lung cancer, Hodgkin’s disease, leukaemia, and others, immuno-oncology therapies are offering patients a new treatment alternative.1 Interest in immuno-oncology has been piqued […]

Market Access
Navigating the future of oncology market access
  • March 29, 2017
  • Valid Insight

According to many payers, the high prices of oncology medicines are not sustainable and there remains a gap between drug price and value.1 The rising costs of drug development, increased clinical demand and the need to recoup the cost of failed products, have led to new cancer treatments that come with a high price tag. […]

Payer-centric post-launch studies for optimal negotiations
  • March 13, 2017
  • Valid Insight

Many healthcare stakeholders want to ensure better health outcomes for patients. However, many new and innovative therapies enter the market with evidence gaps in their value proposition. Since tracking and measuring outcomes entails cost and time, many payers decide to go with simpler and more straightforward financial-based contracting agreements, such as discounting, price-volume agreements, and […]

MEA
Co-creating the design of risk-based managed entry agreements with payers
  • March 3, 2017
  • Valid Insight

Discussions around risk-based managed entry agreements are growing, but only a few of these discussions come to fruition. Such agreements entail risks for both payers and manufacturers. Often, payers do not have the resources or capabilities to perform extensive risk evaluations and standardise value assessment across the board. Subsequently, many payers are sceptical of innovative […]

orphan drug
Patient advocacy as a strategy for orphan drug access
  • February 25, 2017
  • Valid Insight

Governments have integrated incentives to accelerate and promote the approval of orphan drugs and the interest among pharmaceutical companies to develop these products is rising. However, expedited regulatory approval is by no means an assurance that orphan drugs will succeed in the marketplace.

Cell & Gene Therapies
Advances in cell and gene therapies: What does it mean for big pharma?
  • February 6, 2017
  • Valid Insight

Recent years have seen substantial progress in the search for cell and gene therapies, with new medicinal technologies presenting hope for tackling a wide range of diseases.1 Indeed, there are some experimental therapies currently in Phase II and Phase III that are hopeful for launch into the market within the next decade.2 There is tremendous opportunity […]

Formulary Lock Out
Formulary lock out in the US
  • January 29, 2017
  • Valid Insight

Patients in the US often hear the term ‘drug formulary’ when they go to see their physician. A formulary, essentially, is a list of prescription medicines that are readily available in the hospital or that are covered by the patient’s drug insurance plan. The contents of formularies provide a strong reflection of the business priorities […]

Market Access
Valid News, Market Access Insights – Vol 01, Issue 01
  • January 17, 2017
  • Valid Insight

Valid News, Market Access Insights is our new newsletter. In Volume 01, Issue 01, we provide advice on how to weather pricing competition and prepare for reimbursement, as well as explain the role of confidential contracting for flexible pricing. The growing importance of patient-reported outcomes are also discussed. A global market access news round-up and […]